JZJingchen Zhai

Jingchen Zhai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingchen Zhai has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NNKcat: deep neural network to predict catalytic constants (Kcat) by integrating protein sequence and substrate structure with enhanced data imbalance handling

    by Jingchen Zhai, Xiguang Qi, Lianjin Cai, Yue Liu, Haocheng Tang, Lei Xie, Junmei Wang

    Catalytic constant (Kcat) is to describe the efficiency of catalyzing reactions. The Kcat value of an enzyme-substrate pair indicates the rate an enzyme converts saturated substrates into product during the catalytic process. However, it is challenging to construct robust prediction models for this important property. Most of the existing models, including the one recently published by Nature Catalysis (Li et al.), are suffering from the overfitting issue. In this study, we proposed a novel protocol to construct Kcat prediction models, introducing an intermedia step to separately develop substrate and protein processors. The substrate processor leverages analyzing Simplified Molecular Input Line Entry System (SMILES) strings using a graph neural network model, attentive FP, while the protein processor abstracts protein sequence information utilizing long short-term memory architecture. This protocol not only mitigates the impact of data imbalance in the original dataset but also provides greater flexibility in customizing the general-purpose Kcat prediction model to enhance the prediction accuracy for specific enzyme classes. Our general-purpose Kcat prediction model demonstrates significantly enhanced stability and slightly better accuracy (R2 value of 0.54 versus 0.50) in comparison with Li et al.’s model using the same dataset. Additionally, our modeling protocol enables personalization of fine-tuning the general-purpose Kcat model for specific enzyme categories through focused learning. Using Cytochrome P450 (CYP450) enzymes as a case study, we achieved the best R2 value of 0.64 for the focused model. The high-quality performance and expandability of the model guarantee its broad applications in enzyme engineering and drug research & development.


  • Open Access

    Advancing promiscuous aggregating inhibitor analysis with intelligent machine learning classification

    by Luxuan Wang, Beihong Ji, Jingchen Zhai, Junmei Wang

    Small molecules have been playing a crucial role in drug discovery; however, some exhibit nonspecific inhibitory effects during hit screening due to the formation of colloidal aggregators. Such false positives often lead to significant research costs and time investment. Therefore, to identify potential aggregating compounds efficiently and accurately at an early stage of drug discovery, we employed several machine learning techniques to develop classification models for identifying promiscuous aggregating inhibitors. Using a training dataset of 10 000 aggregators and 10 000 nonaggregators, models were trained by combining four different molecular representations with various machine learning algorithms. We found that the best-performing model is the one that employs path-based FP2 fingerprints in conjunction with the cubic support vector machine algorithm, which achieved the highest accuracy and area under the receiver operating characteristic curve values for both the validation and test datasets while maintaining high sensitivity and specificity levels (>0.93). Additionally, we have proposed a new model interpretation method, global sensitivity analysis (GSA), to complement the well-recognized SHapley Additive exPlanations analysis. Several comparative studies have shown that GSA is a time-efficient and accurate approach for identifying crucial descriptors that contribute to model prediction, especially in the scenario where the dataset contains a substantial number of data entries with a limited set of descriptors. Our models as well as GSA findings can provide useful guidance on screening library design to minimize false positives.


  • Open Access

    Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain

    by Lianjin Cai, Jingchen Zhai, Beihong Ji, Fengyang Han, Taoyu Niu, Luxuan Wang, Junmei Wang

    Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for children. However, the current dose regimen in pediatric populations relies on clinical expertise while the pharmacokinetics properties are poorly understood. This study aimed to develop diamorphine population pharmacokinetics (pop‐PK) models and simulate the IND dosing in virtual pediatric subjects. An integrated four‐compartment pop‐PK model with first‐order absorption and elimination provided an appropriate fit and characterized publicly available 385 concentration measurements of diamorphine, 6‐monoacetylmorphine, and morphine collected from adults. Body weight allometry and renal function maturation (age) were incorporated into the final model, serving as two covariates. The estimated IND relative bioavailability was around 52% compared with intramuscularly injected diamorphine. Using this final model, the morphine plasma concentrations, as the active metabolite for pain relief, were simulated in virtual subjects. The utility of model extrapolation was supported by external verification with acceptable average fold errors of 1.06 ± 0.30 and 0.83 ± 0.07 for morphine maximum concentration and exposures. Meanwhile, the simulated morphine concentration–time profiles could recover the PK profiles observed in children after a single dose of IND. The model‐based dosing simulations were therefore assessed in four children age groups to match the therapeutic window of morphine concentrations in steady state (10–20 μg/L). Our study demonstrates that the dose regimen of 0.3 mg/kg loading dose plus 0.1 mg/kg hourly maintenance dose is generally appropriate for multiple pediatric populations with breakthrough pain, in the view of PK.


  • Open Access

    Geometry Optimization Algorithms in Conjunction with the Machine Learning Potential ANI-2x Facilitate the Structure-Based Virtual Screening and Binding Mode Prediction

    by Luxuan Wang, Xibing He, Beihong Ji, Fengyang Han, Taoyu Niu, Lianjin Cai, Jingchen Zhai, Dongxiao Hao, Junmei Wang

    Structure-based virtual screening utilizes molecular docking to explore and analyze ligand–macromolecule interactions, crucial for identifying and developing potential drug candidates. Although there is availability of several widely used docking programs, the accurate prediction of binding affinity and binding mode still presents challenges. In this study, we introduced a novel protocol that combines our in-house geometry optimization algorithm, the conjugate gradient with backtracking line search (CG-BS), which is capable of restraining and constraining rotatable torsional angles and other geometric parameters with a highly accurate machine learning potential, ANI-2x, renowned for its precise molecular energy predictions reassembling the wB97X/6-31G(d) model. By integrating this protocol with binding pose prediction using the Glide, we conducted additional structural optimization and potential energy prediction on 11 small molecule–macromolecule and 12 peptide–macromolecule systems. We observed that ANI-2x/CG-BS greatly improved the docking power, not only optimizing binding poses more effectively, particularly when the RMSD of the predicted binding pose by Glide exceeded around 5 Å, but also achieving a 26% higher success rate in identifying those native-like binding poses at the top rank compared to Glide docking. As for the scoring and ranking powers, ANI-2x/CG-BS demonstrated an enhanced performance in predicting and ranking hundreds or thousands of ligands over Glide docking. For example, Pearson’s and Spearman’s correlation coefficients remarkedly increased from 0.24 and 0.14 with Glide docking to 0.85 and 0.69, respectively, with the addition of ANI-2x/CG-BS for optimizing and ranking small molecules binding to the bacterial ribosomal aminoacyl-tRNA receptor. These results suggest that ANI-2x/CG-BS holds considerable potential for being integrated into virtual screening pipelines due to its enhanced docking performance.


  • Open Access

    In Silico Screening of Natural Flavonoids against 3-Chymotrypsin-like Protease of SARS-CoV-2 Using Machine Learning and Molecular Modeling

    by Lianjin Cai, Fengyang Han, Beihong Ji, Xibing He, Luxuan Wang, Taoyu Niu, Jingchen Zhai, Junmei Wang

    The “Long-COVID syndrome” has posed significant challenges due to a lack of validated therapeutic options. We developed a novel multi-step virtual screening strategy to reliably identify inhibitors against 3-chymotrypsin-like protease of SARS-CoV-2 from abundant flavonoids, which represents a promising source of antiviral and immune-boosting nutrients. We identified 57 interacting residues as contributors to the protein-ligand binding pocket. Their energy interaction profiles constituted the input features for Machine Learning (ML) models. The consensus of 25 classifiers trained using various ML algorithms attained 93.9% accuracy and a 6.4% false-positive-rate. The consensus of 10 regression models for binding energy prediction also achieved a low root-mean-square error of 1.18 kcal/mol. We screened out 120 flavonoid hits first and retained 50 drug-like hits after predefined ADMET filtering to ensure bioavailability and safety profiles. Furthermore, molecular dynamics simulations prioritized nine bioactive flavonoids as promising anti-SARS-CoV-2 agents exhibiting both high structural stability (root-mean-square deviation < 5 Å for 218 ns) and low MM/PBSA binding free energy (<−6 kcal/mol). Among them, KB-2 (PubChem-CID, 14630497) and 9-O-Methylglyceofuran (PubChem-CID, 44257401) displayed excellent binding affinity and desirable pharmacokinetic capabilities. These compounds have great potential to serve as oral nutraceuticals with therapeutic and prophylactic properties as care strategies for patients with long-COVID syndrome.


  • Open Access

    Toward Predicting Solubility of Arbitrary Solutes in Arbitrary Solvents. 1: Prediction of Density and Refractive Index Using Machine Learning Algorithms with correlation-group parallel feature analysis

    by Brian Hu, Jingchen Zhai, Xiguang Qi, Xibing He, Junmei Wang

    Density and refractive index (nD) are two important properties related to van der Waals energy of a molecule. Thus, accurate prediction of these two properties has a great value in both molecular mechanics force field development, and solvation free energy and solubility prediction of any arbitrary molecules. In this study, we gathered molecule characteristics information of roughly 5,000 organic compounds for density records and 4000 organic compounds for nD values. Subsequently, the distinct GAFF (General AMBER Force Field) descriptors and RDkit descriptors of the compounds were generated and then applied to train various prediction models with a variety of machine learning algorithms for both properties respectively. As a result, both GAFF and RDkit descriptors yielded various robust models with low average percent errors (APE), low root-mean-square errors (RMSE) and high correlation coefficients R-square, while RDkit showed slightly better performance for predicting both properties. We further optimized top models and conducted parallel feature analysis (PFA) to identify specific features in each descriptor which outstandingly contributed to model robustness. The final model RMSE is 0.071 g/cm3 for density prediction and 0.014 for nD prediction, the APE value is as low as 2.845% for density and 0.531% for nD, and R-square is 0.950 for density and 0.954 for nD. Note that the performance of our prediction models for both density and nD significantly outperforms all currently published studies, especially for those with a dataset containing more than 200 records. The successful prediction of the two key molecular properties paves the road towards accurately predicting solubility of an arbitrary solute in an arbitrary solvent, an endeavor not only facilitates pharmaceutical industry to develop better drug candidates, but also increases efficiency regarding overall wet lab work. Key predictors which contribute most to a specific model or model function were identified using both Shapley analysis and correlation-group parallel feature analysis (CG-PFA).

  • Open Access

    Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations

    by Jingchen Zhai, Beihong Ji, Lianjin Cai, Shuhan Liu, Yuchen Sun, Junmei Wang

    Malaria is a severe parasite infectious disease with high fatality. As one of the approved treatments of this disease, hydroxychloroquine (HCQ) lacks clinical administration guidelines for patients with special health conditions and co-morbidities. This may result in improper dosing for different populations and lead them to suffer from severe side effects. One of the most important toxicities of HCQ overdose is cardiotoxicity. In this study, we built and validated a physiologically based pharmacokinetic modeling (PBPK) model for HCQ. With the full-PBPK model, we predicted the pharmacokinetic (PK) profile for malaria patients without other co-morbidities under the HCQ dosing regimen suggested by Food and Drug Administration (FDA) guidance. The PK profiles for different special populations were also predicted and compared to the normal population. Moreover, we proposed a series of adjusted dosing regimens for different populations with special health conditions and predicted the concentration-time (C-T) curve of the drug plasma concentration in these populations which include the pregnant population, elderly population, RA patients, and renal impairment populations. The recommended special population-dependent dosage regimens can maintain the similar drug levels observed in the virtual healthy population under the original dosing regimen provided by FDA. Last, we developed mathematic formulas for predicting dosage based on a patient’s body measurements and two indexes of renal function (glomerular filtration rate and serum creatine level) for the pediatric and morbidly obese populations. Those formulas can facilitate personalized treatment of this disease. We hope to provide some advice to clinical practice when taking HCQ as a treatment for malaria patients with special health conditions or co-morbidities so that they will not suffer from severe side effects due to higher drug plasma concentration, especially cardiotoxicity.


  • In Silico Prediction of Pharmacokinetic Profile for Human Oral Drug Candidates Which Lack Clinical Pharmacokinetic Experiment Data

    by Jingchen Zhai, Beihong Ji, Shuhan Liu, Yuzhao Zhang, Lianjin Cai, Junmei Wang

    Backgrounds and Objectives In silico methods which can generate high-quality physiologically based pharmacokinetic (PBPK) models for arbitrary drug candidates are greatly needed to select developable drug candidates that escape drug attrition because of the poor pharmacokinetic profile. The purpose of this study is to develop a novel protocol to preliminarily predict the concentration profile of a target drug based on the PBPK model of a structurally similar template drug by combining two software platforms for PBPK modeling, the SimCYP simulator and ADMET Predictor. Methods The method was evaluated by utilizing 13 drug pairs from 18 drugs in the built-in database of the SimCYP software. All drug pairs have Tanimoto scores (TS) no less than 0.5. As each drug in a drug pair can serve as both target and template, 26 sets were studied in this work. Three versions (V1, V2 and V3) of models for the target drug were constructed by replacing the corresponding parameters of the template drug step by step with those predicted by ADMET Predictor for the target drug. V1 represents the replacement of molecular weight (MW), V2 includes the replacement of parameter MW, fraction unbound in plasma (fu), blood-to-plasma partition ratio (B/P), logarithm of the octanol-buffer partition coefficient (log Po:w) and acid dissociation constant (pKa). In V3, all above-mentioned parameters as well as human jejunum effective permeability (Peff), Vd and cytochrome P450 (CYP) metabolism parameters (Km, Vmax or CLint) are modified. Normalized root mean square error (NRMSE) was used for the evaluation of the model performance. Results We found that the performance of the three versions of the models depends on structural similarity of the drug pairs. For Group I drug pairs (TS ≤ 0.7), V2 and V3 performed better than V1 in terms of NRMSE; for Group II drug pairs (0.7 < TS ≤ 0.9), 8 out of 10 V3 models had NRMSE < 0.2, the cutoff we applied to judge whether the simulated concentration-time (C–T) curve was satisfactory or not. V3 outperformed the V1 and V2 versions. For the two drug pairs belonging to Group III (TS > 0.9), V2 outperformed V1 and V3, suggesting more unnecessary replacement can lower the performance of PBPK models. We also investigated how the prediction accuracy of ADMET Predictor as well as its collaboration with SimCYP influences the quality of PBPK models constructed using SimCYP. Conclusion In conclusion, we generated practical guidance on applying two mainstream software packages, ADMET Predictor and SimCYP, to construct PBPK models for drugs or drug candidates that lack ADME parameters in model construction.


  • A multiple-step in silico screening protocol to identify allosteric inhibitors of Spike–hACE2 binding

    by Jingchen Zhai, Xibing He, Viet Hoang Man, Yuchen Sun, Beihong Ji, Lianjin Cai, Junmei Wang

    While the COVID-19 pandemic continues to worsen, effective medicines that target the life cycle of SARS-CoV-2 are still under development. As more highly infective and dangerous variants of the coronavirus emerge, the protective power of vaccines will decrease or vanish. Thus, the development of drugs, which are free of drug resistance is direly needed. The aim of this study is to identify allosteric binding modulators from a large compound library to inhibit the binding between the Spike protein of the SARS-CoV-2 virus and human angiotensin-converting enzyme 2 (hACE2). The binding of the Spike protein to hACE2 is the first step of the infection of host cells by the coronavirus. We first built a compound library containing 77 448 antiviral compounds. Molecular docking was then conducted to preliminarily screen compounds which can potently bind to the Spike protein at two allosteric binding sites. Next, molecular dynamics simulations were performed to accurately calculate the binding affinity between the spike protein and an identified compound from docking screening and to investigate whether the compound can interfere with the binding between the Spike protein and hACE2. We successfully identified two possible drug binding sites on the Spike protein and discovered a series of antiviral compounds which can weaken the interaction between the Spike protein and hACE2 receptor through conformational changes of the key Spike residues at the Spike–hACE2 binding interface induced by the binding of the ligand at the allosteric binding site. We also applied our screening protocol to another compound library which consists of 3407 compounds for which the inhibitory activities of Spike/hACE2 binding were measured. Encouragingly, in vitro data supports that the identified compounds can inhibit the Spike–ACE2 binding. Thus, we developed a promising computational protocol to discover allosteric inhibitors of the binding of the Spike protein of SARS-CoV-2 to the hACE2 receptor, and several promising allosteric modulators were discovered.


  • Open Access

    A New Approach for In Silico Prediction of Oral Drug Concentration Profiles in Human for Drug Candidates Lack Experimental Pharmacokinetic Data

    by Jingchen Zhai, Beihong Ji, Shuhan Liu, Yuzhao Zhang, Junmei Wang

    The purpose of this study is to develop a novel protocol to preliminarily predict the concentration profiles of a target drug based on the PBPK model of a structurally similar template drug by combining two software for PBPK modeling, the SimCYP simulator and ADMET Predictor. The method was evaluated by utilizing 13 drug pairs which come from 18 drugs in the built-in database of the SimCYP software. All drug pairs have their Tanimoto scores no less than 0.5. As each drug in a drug pair can serve both the target and template roles, in total, there are 26 sets studied in this work. Three versions (V1, V2 and V3) of models for the target drug were constructed by replacing the corresponding parameters of the template drug step by step with those predicted by ADME Predictor for the target drug. Normalized RMSE (NRMSE) were introduced for the evaluation of the model performance. We found that the performance of the three versions of models depends on structure similarity of the drug pairs. For Group I drug pairs (TS ≤ 0.7), V2 and V3 perform better than V1 in term of NRMSE; for Group II drug pairs (0.7 < TS ≤ 0.9), 8 out of 10 V3 models have NRMSE lower than 0.2, the cutoff we applied to judge if the simulated C-T curve is satisfactory or not. Obviously, V3 outperforms the V1 and V2 versions. For the two drug pairs belong to Group III (TS > 0.9), V2 outperforms V1 and V3, suggesting more unnecessary replacement can lower the performance of PBPK models. We also investigated how the prediction accuracy of ADMET Predictor as well as its collaboration with SimCYP influence the quality of PBPK models constructed using SimCYP. In conclusion, we generated a practical guidance on applying two mainstream software packages, ADMET Predictor and SimCYP, to construct PBPK models for drugs or drug candidates which lack of ADME parameters in model construction.